[1] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/CD]. 肿瘤综合治疗电子杂志, 2022, 8(2):16-53. [2] ZHOU M, WANG H, ZENG X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. [3] CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. [4] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. [5] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma[J]. J Hepatol, 2018, 69(1):182-236. [6] 李晓月,李述捷,易永祥.乙型肝炎病毒和丙型肝炎病毒相关性肝癌的研究进展[J/CD].新发传染病电子杂志,2022,7(1):92-99. [7] DESMET VJ.East-West pathology agreement on precancerous liver lesions and early hepatocellular carcinoma[J]. Hepatology. 2009,49(2):355-357. [8] SCIARRA A, DI TOMMASO L, NAKANO M, et al.Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications[J]. J Hepatol, 2016, 64(1):87-93. [9] MOTOSUGI U, BANNAS P, SANO K, et al.Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma[J]. J Magn Reson Imaging,2015, 41(2):251-265. [10] THE WHO CLASSIFICATION OF TUMOURS EDITORIAL BOARD. WHO classification of tumours of the digestive system[M]. 5th ed. Lyon: IARC Press, 2019:227-238. [11] INTERNATIONAL CONSENSUS GROUP FOR HEPATOCELLULAR NEOPLASIA, THE INTERNATIONAL CONSENSUS GROUP FOR HEPATOCELLULAR NEOPLASIA. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia[J]. Hepatology, 2009, 49(2): 658-664. [12] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J].中华肝脏病杂志, 2015, 23(5): 321‐327. [13] GHOLAMI S, PERRY LM, DENBO JW, et al.Management of early hepatocellular carcinoma: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association[J]. HPB (Oxford), 2021,23(5):753-761. [14] CHOI YR, CHUNG JW, KIM JH, et al.Cone‐beam computed tomography‐hepatic arteriography as a diagnostic tool for small hypervascular hepatocellular carcinomas: method and clinical implications[J]. Korean J Radiol, 2020, 21(3): 306-315. [15] GUYATT G,OXMAN AD,AKL EA,et al.GRADE guide-lines: Introduction-GRADE evidence profiles and summary of findings tables[J].J Clin Epidemiol,2011,64(4):383-394. [16] BALSHEM H,HELFAND M,SCHUNEMANN HJ,et al.GRADE guidelines: Rating the quality of evidence[J].J Clin Epidemiol,2011,64(4): 401-406. [17] ANDREWS JC,SCHUNEMANN HJ,OXMAN AD,et al.GRADE guidelines: Going from evidence to recommendation determinants of a recommendation's direction and strength[J].J Clin Epidemiol, 2013, 66(7): 726-735. [18] GIORGIO A, CALISTI G, DI SARNO A,et al.Characterization of dysplastic nodules, early hepatocellular carcinoma and progressed hepatocellular carcinoma in cirrhosis with contrast-enhanced ultrasound[J]. Anticancer Res, 2011,31(11):3977-3982. [19] BOOZARI B, SOUDAH B, RIFAI K, et al.Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study[J]. Dig Liver Dis, 2011,43(6):484-490. [20] LEONI S, PISCAGLIA F, GRANITO A, et al.Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted[J]. Ultraschall Med, 2013,34(3):280-287. [21] ZHANG W, CHEN HJ, WANG ZJ,et al.Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model[J]. Eur Radiol, 2017,27(5):2086-2094. [22] SCHELLHAAS B,STROBEL D.Tips and Tricks in Contrast-Enhanced Ultrasound(CEUS)for the Characterization and Detection of Liver Malignancies[J]. Ultraschall Med, 2019, 40(4):404-424. [23] KIM BS, ANGTHONG W, JEON YH,et al.Body MR imaging: fast, efficient, and comprehensive[J]. Radiol Clin North Am, 2014,52(4):623-636. [24] HWANG J, KIM YK, JEONG WK, et al.Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization[J]. Radiology, 2015,276(1):137-146. [25] RENZULLI M, BISELLI M, BROCCHI S, et al.New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm[J]. Gut, 2018,67(9):1674-1682. [26] 何家伟,徐志锋,侯诗楠.MR扩散加权成像定量化分析在预测小肝癌分化程度的价值[J].临床放射学杂志,2017,36(10):1452-1455. [27] TAKAHASHI M, MARUYAMA H, SHIMADA T, et al.Characterization of hepatic lesions (≤30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging[J]. Eur J Radiol, 2013,82(1):75-84. [28] SANO K, ICHIKAWA T, MOTOSUGI U, et al.Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging[J]. Radiology, 2011, 261(3):834-844. [29] LEE YJ, LEE JM, LEE JS,et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology, 2015,275(1):97-109. [30] RAO SX, WANG J, WANG J, et al.Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium[J]. J Dig Dis, 2019,20(2):54-61. [31] 杜艳妮,吕志彬,邢玉雪,等.乙型肝炎背景下肝细胞肝癌钆塞酸二钠增强MRI与组织学分化程度相关性分析[J/CD].新发传染病电子杂志,2022, 7(4):47-52. [32] CHEN Q, WANG M, WANG M, et al.Expansile invasive growth pattern is definite evidence for the diagnosis of small hepatocellular carcinomas: a comparative study of 37 cases[J]. Hum Pathol, 2018,80:130-137. [33] NAKANO M, SAITO A, YAMAMOTO M, et al.Stromal and blood vessel wall invasion in well-differentiated hepatocellular carcinoma[J]. Liver, 1997,17(1):41-46. [34] 陈琼荣. 早期小HCC的病理特征[J]. 中华病理学杂志, 2020, 49(12):1353-1357. [35] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER, EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER. Clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4):908-943. [36] TERRAULT NA, LOK ASF, MCMAHON BJ, et al.Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Clin Liver Dis, 2018,12(1):33-34. [37] OMATA M, CHENG AL, KOKUDO N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370. [38] CHEN L, ABOU-ALFA GK, ZHENG B, et al.Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients[J]. Cell Res, 2021, 31(5):589-592. [39] HEIMBACH JK, KULIK LM, FINN RS, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018,67(1):358-380. [40] MARRERO JA, KULIK LM, SIRLIN CB, et al.Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018 ,68(2):723-750. [41] 伍秋艳,刘娟,杨崇双,等. 影像学检查在诊断小肝癌中的应用价值[J]. 中华消化外科杂志,2022,21(4):543-550. [42] SUGIMOTO K, MORIYASU F, SHIRAISHI J, et al.Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging[J]. Eur Radiol, 2012, 22(6):1205-1213. |